Researchers are shining a light on cancer cells’ energy centers – literally – to damage these power sources and trigger widespread cancer cell death.
Novartis to seek accelerated approval for oral complement inhibitor in rare kidney disease
Novartis said that its experimental complement inhibitor iptacopan reduced the buildup of protein in the urine of patients with IgA nephropathy significantly more than a
October 3, 2023